prinaberel

Prinaberel is a synthetic, nonsteroidal, and highly selective agonist of the estrogen receptor beta (ERβ). It was developed as an orally active small molecule by Wyeth for potential use in treating inflammatory and gynecological conditions. Prinaberel has been investigated for diseases such as endometriosis, Crohn's disease, rheumatoid arthritis, and interstitial cystitis. Its mechanism of action involves selective activation of the estrogen receptor beta subtype, which is thought to mediate anti-inflammatory effects and modulate cell proliferation. Although it showed promise in preclinical studies and early clinical trials (reaching up to Phase II), development was discontinued for all major indications due to lack of sufficient efficacy or strategic reasons[1][2][3][4][5][6]. Prinaberel also demonstrated chemopreventive activity against skin cancer in preclinical models by dampening WNT/β-catenin signaling pathways[7][8]. The drug does not have any approved brand names or marketed formulations.

Other names

prinaberelPrinaberel [USAN]